Physician profile
Eric E Elgin
NPI 1831104587
$29,205.67
in general payments reported to CMS, 2019-2025
27 companies · $2,869 in 2025
The $2,869 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,322 · 2020: $496 · 2021: $513 · 2022: $5,320 · 2023: $7,273 · 2024: $10K · 2025: $2,869.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $12K · Food and Beverage: $8,396 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $12,028.98 |
| Food and Beverage | $8,396.05 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $130.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $8,301.17 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Mitraclip, Triclip |
| Ge Healthcare | $7,888.53 | 2024-2025 | |
| Medtronic, INC. | $5,782.39 | 2022-2025 | Corevalve Evolut R, Symplicity G3, Onyx Frontier |
| Boston Scientific Corporation | $1,751.33 | 2019-2024 | Watchman Flx, Avvigo Guidance System |
| Edwards Lifesciences Corporation | $1,445.13 | 2019-2025 | Sapien 3 Ultra Resilia, Evoque, Pascal |
| Heartflow, INC. | $1,137.90 | 2024 | |
| Philips North America LLC | $934.17 | 2019-2025 | Azurion 7 M20, (S33) Igt Fs Eq Undivided |
| Abiomed | $714.43 | 2021-2025 | Impella |
| Shockwave Medical, INC | $469.40 | 2023-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Biosense Webster, INC. | $137.64 | 2022 | |
| Cathworks, INC. | $115.20 | 2023-2024 | Ffrangio |
| Janssen Pharmaceuticals, INC | $93.97 | 2019-2022 | |
| Recor Medical INC | $83.45 | 2025 | Paradise Ultrasound Renal Denervation System |
| Medtronic Vascular, INC. | $71.43 | 2020 | |
| Chiesi USA, INC. | $43.84 | 2019-2023 | Kengreal |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardinal Health 200 LLC | $38.36 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $27.03 | 2019 | |
| Pfizer INC. | $23.65 | 2021 | |
| Cardiovascular Systems INC. | $22.65 | 2020-2022 | |
| Livanova USA, INC. | $22.18 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $17.19 | 2019 | |
| Novartis Pharmaceuticals Corporation | $16.15 | 2019 | |
| Sanofi-Aventis U.S. LLC | $14.50 | 2019 | |
| Siemens Medical Solutions USA, INC. | $14.40 | 2019 | |
| United Therapeutics Corporation | $13.68 | 2019 | |
| Cook Medical LLC | $13.48 | 2019 | |
| Amgen INC. | $12.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Elgin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.